title,time_published,url,ticker,relevance_score,ticker_sentiment_label,ticker_sentiment_score
"Geographic Atrophy Market to Boost Significantly, Assesses DelveInsight | Key Companies Active in the Domain - Novartis, Annexon, Apellis, Ionis, Astellas, Gyroscope, Genentech, Aviceda, Iveric Bio",20230628T210100,https://www.prnewswire.com/news-releases/geographic-atrophy-market-to-boost-significantly-assesses-delveinsight--key-companies-active-in-the-domain---novartis-annexon-apellis-ionis-astellas-gyroscope-genentech-aviceda-iveric-bio-301865699.html,ALPMF,0.025845,Neutral,0.007551
"Neuropathy Pain Treatment Market size to grow by USD 5.84 billion from 2023 to 2028, North America accounts for 33 ... - PR Newswire",20231214T221500,https://www.prnewswire.com/news-releases/neuropathy-pain-treatment-market-size-to-grow-by-usd-5-84-billion-from-2023-to-2028--north-america-accounts-for-33-of-market-growth--technavio-302015282.html,ALPMF,0.078099,Neutral,0.0
"Cutaneous Melanoma Market is Predicted to Exhibit Remarkable Growth, Predicts DelveInsight | Key Companies - Merck, Amgen, Anaveon, Eisai, Regeneron, BMS, AstraZeneca, Seagen, Novartis, Eli Lilly and Company",20230724T210100,https://www.prnewswire.com/news-releases/cutaneous-melanoma-market-is-predicted-to-exhibit-remarkable-growth-predicts-delveinsight--key-companies---merck-amgen-anaveon-eisai-regeneron-bms-astrazeneca-seagen-novartis-eli-lilly-and-company-301883725.html,ALPMF,0.05381,Neutral,0.031999
Markets Open Higher; US Goods Gap Narrows To $104.3B In May,20220628T135744,https://www.benzinga.com/news/earnings/22/06/27882740/markets-open-higher-us-goods-gap-narrows-to-104-3b-in-may,ALPMF,0.068482,Neutral,0.120396
Astellas and Poseida Therapeutics Enter Into Research Collaboration and License Agreement to Develop Novel Allogeneic Cell Therapies in Oncology,20240501T130000,https://www.prnewswire.com/news-releases/astellas-and-poseida-therapeutics-enter-into-research-collaboration-and-license-agreement-to-develop-novel-allogeneic-cell-therapies-in-oncology-302133127.html,ALPMF,0.108344,Somewhat-Bullish,0.152842
"Gene therapy market size to grow by USD 4.61 billion from 2022 to 2027, North America is estimated to contribute 39 ... - PR Newswire",20240318T093600,https://www.prnewswire.com/news-releases/gene-therapy-market-size-to-grow-by-usd-4-61-billion-from-2022-to-2027--north-america-is-estimated-to-contribute-39-to-the-growth-technavio-302090363.html,ALPMF,0.033562,Neutral,0.019119
"Gene therapy market size to grow by USD 4,613.9 million from 2022 to 2027 | Growing research in gene therapy for ... - PR Newswire",20231201T073500,https://www.prnewswire.com/news-releases/gene-therapy-market-size-to-grow-by-usd-4-613-9-million-from-2022-to-2027--growing-research-in-gene-therapy-for-cvds-and-orphan-diseases-is-the-major-market-trend--technavio-302002646.html,ALPMF,0.048523,Neutral,0.017903
Poseida Therapeutics Provides Updates and Financial Results for the Third Quarter of 2023,20231109T210500,https://www.prnewswire.com/news-releases/poseida-therapeutics-provides-updates-and-financial-results-for-the-third-quarter-of-2023-301983952.html,ALPMF,0.019879,Neutral,0.0
"Gene Therapy Market size to grow by USD 4.61 billion from 2022 to 2027, North America to account for 39% of market ... - PR Newswire",20231103T223500,https://www.prnewswire.com/news-releases/gene-therapy-market-size-to-grow-by-usd-4-61-billion-from-2022-to-2027--north-america-to-account-for-39-of-market-growth--technavio-301976707.html,ALPMF,0.074692,Neutral,0.0
Poseida Therapeutics Announces Leadership Transition,20231009T203000,https://www.prnewswire.com/news-releases/poseida-therapeutics-announces-leadership-transition-301951263.html,ALPMF,0.03463,Neutral,0.048111
Why Are Poseida Therapeutics Shares Moving Higher Today? - Poseida Therapeutics  ( NASDAQ:PSTX ) ,20230807T145554,https://www.benzinga.com/general/biotech/23/08/33601799/why-are-poseida-therapeutics-shares-moving-higher-today,ALPMF,0.197413,Somewhat-Bullish,0.166805
Astellas and Poseida Therapeutics Announce Strategic Investment to Support Poseida's Commitment to Redefining Cancer Cell Therapy,20230807T130000,https://www.prnewswire.com/news-releases/astellas-and-poseida-therapeutics-announce-strategic-investment-to-support-poseidas-commitment-to-redefining-cancer-cell-therapy-301894277.html,ALPMF,0.054359,Neutral,0.121979
Medical Second Opinion Global Market to Register Stunning Growth at a CAGR of ~17% by 2028 | DelveInsight,20230821T210100,https://www.prnewswire.com/news-releases/medical-second-opinion-global-market-to-register-stunning-growth-at-a-cagr-of-17-by-2028--delveinsight-301905294.html,ALPMF,0.024347,Neutral,-0.03954
"Nasdaq Surges Over 200 Points; General Electric Posts Downbeat Earnings - Compass  ( NYSE:COMP ) , Crown Holdings  ( NYSE:CCK ) ",20221025T183312,https://www.benzinga.com/news/earnings/22/10/29404553/nasdaq-surges-over-200-points-general-electric-posts-downbeat-earnings,ALPMF,0.073321,Neutral,0.052406
"S&P 500 Rises Over 1%; General Motors Earnings Top Views - General Motors  ( NYSE:GM ) , Crown Holdings  ( NYSE:CCK ) ",20221025T162029,https://www.benzinga.com/news/earnings/22/10/29402307/s-p-500-rises-over-1-general-motors-earnings-top-views,ALPMF,0.07031,Neutral,0.0521
Why CytomX Therapeutics  ( CTMX )  Shares Are Falling Today - CytomX Therapeutics  ( NASDAQ:CTMX ) ,20230328T153514,https://www.benzinga.com/general/biotech/23/03/31531824/abbvie-walks-away-from-cytomx-partnership-but-garnering-attention-of-big-pharma-partners,ALPMF,0.277433,Neutral,0.0
Best Penny Stocks To Buy Now? 5 Biotech Stocks To Watch This Week,20221121T175936,https://pennystocks.com/featured/2022/11/21/best-penny-stocks-to-buy-now-5-biotech-stocks-to-watch-this-week/,ALPMF,0.035035,Neutral,0.133248
